Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04778059 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
A Phase 2 study, sponsored by US Biotest.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT04778059 is a Phase 2 study that was terminated before completion, run by US Biotest. The registered enrollment target is 21 participants.
The verdict
NCT04778059, a Phase 2 study, was terminated before completion, sponsored by US Biotest.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.
Interventions
- DRUG Placebo
- DRUG USB002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2022-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04778059
The ClinicalTrials.gov registry entry for NCT04778059 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Biotest, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04778059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04778059 about?
NCT04778059 is a clinical study titled "Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19". This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.
What is the current status of trial NCT04778059?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2021-07-27. Estimated completion is 2022-05-10.
What interventions are being tested in trial NCT04778059?
The interventions under investigation include: Placebo (DRUG), USB002 (DRUG).
Who is sponsoring clinical trial NCT04778059?
This trial is sponsored by US Biotest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.